Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biolojic Design Ltd.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Jun 4, 2024
Deals
Deals Report: Two pharmas license neuro assets, and M&A momentum continues
Plus: Galapagos-Adaptimmune enter TCR T cell deal, and digital therapeutics pioneer Akili opts for merger
BioCentury | May 16, 2024
Deals
With Proteologix takeout, J&J adds bispecifics for atopic dermatitis, asthma
Lead compound targeting IL-13 and TSLP trails bispecific competitors; second program set to advance behind it
BioCentury | Apr 30, 2024
Deals
Deals Report: BMS-Repertoire to develop vaccines for autoimmunity
Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
BioCentury | Jan 10, 2024
Data Byte
TSLP mAbs for asthma behind Tezspire
At least eight mAbs in development; two also hit IL-13
BioCentury | Sep 14, 2022
Management Tracks
AZ and Novartis veteran Tommasi to lead R&D at Dunad
Plus new CSOs at Atomwise and Sotio, and updates from Nine Square, Fabric and Biolojic Design
BioCentury | Aug 27, 2021
Finance
Rising aMoon and its growing portfolio at the healthcare-tech interface
Israeli VC has a stable of 36 therapeutics, health-tech plays, with plans to ramp up company creation
BioCentury | Mar 8, 2021
Deals
March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor
Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune company said parent Roivant Sciences Ltd. plans to propose an offer to acquire the 42.5% of outstanding shares
BioCentury | Jan 20, 2021
Emerging Company Profile
Aulos: Tackling the IL-2 space with computational biology
Emerging Company Profile: Aulos believes its computationally designed mAb will stand out in IL-2
Items per page:
1 - 10 of 10